Heart expertise now MOZ.
Back to osteoarthritis 2b publication. I believe a manuscript has been submitted. It will be reviewed by international osteoarthritis clinical trial experts. They will be screened for conflict of interest. I demand release of the independent expert opinion that the chief editor who will summarise the reviewers opinion on quality of data and share it with PAR. PAR has some rejection or criticism which we should know about. If there are serious flaws in this manuscript the value of the company will be cash on hand.
Heart expertise now MOZ. Back to osteoarthritis 2b publication....
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 77810 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 22.0¢ | 23000 | 2 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |